Comparing the current results to its competitors, Immuneering reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 62.91 %, recorded in the same quarter.
Immuneering's Comment on Competition and Industry Peers
The company faces competition from larger pharmaceutical and biotechnology firms, academic institutions, governmental agencies, and public and private research organizations. Its oncology programs targeting the MAPK pathway may compete with FDA-approved therapies and clinical programs focused on RAS or RAF mutant tumors developed by other pharmaceutical and biotechnology companies. Key competitive factors include safety, efficacy, administration ease, pricing, brand recognition, and reimbursement coverage. The company highlights its proprietary platform and scientific expertise while recognizing the rapid development of new technologies and the importance of intellectual property protection in the industry.
September 10, 2025
Pancreatic cancer remains one of the most formidable challenges in oncology, characterized by its aggressive nature and high mortality rates. In recent years, innovation in therapeutic strategies has gained momentum, with various candidates emerging from clinical trials. Among these, Immuneering Corporation, a biotechnology company focused on drug discovery and development, has made significant contributions to the treatment landscape for first-line pancreatic cancer. This article synthesizes key insights from Immuneering’s recent announcements, including updated survival data from their Phase 2a clinical trials and financial performance for the year ending 2024, highlighting their commitment toward advan...
September 12, 2024
In a remarkable stride towards transforming pancreatic cancer therapies, Immuneering Corporation has unveiled positive initial data from its Phase 2a clinical trial of IMM-1-104. This investigational agent, in synergy with chemotherapy, is being tested as a first-line treatment for patients struggling with this aggressive and notoriously difficult-to-treat malignancy. The findings signal a promising future in the battle against pancreatic cancer, showcasing complete and partial responses that are igniting hope within the medical community and among patients and their families.Pancreatic cancer remains one of the most formidable adversaries in oncology, characterized by late detection, poor prognosis, and lim...
July 31, 2024
In a significant development for the treatment of pancreatic cancer, Immuneering Corporation has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, IMM-1-104. This designation is particularly noteworthy as it accelerates the clinical development of medications attending to serious conditions that fill an unmet medical need, potentially leading to expedited market access.The Fast Track designation is granted to therapies that demonstrate the ability to treat, diagnose, or prevent serious conditions, and such an advancement is crucial given the high mortality rate associated with pancreatic ductal adenocarcinoma (PDAC). According to the American Cance...
March 14, 2024
In the world of pharmaceutical sciences, groundbreaking clinical trials often set the stage for the development of revolutionary therapies. Recent positive topline results from the phase 1 portion of Immuneering s phase 1/2a clinical trial of IMM-1-104 in RAS-mutant solid tumors have generated considerable excitement within the scientific community. This article aims to interpret the findings, outline the significant facts, and assess their potential impact on the company. Immuneering s Phase 1 Clinical Trial:Immuneering, a prominent pharmaceutical company focused on developing innovative therapies, recently completed the phase 1 portion of its clinical trial for IMM-1-104. This drug shows immense promise in...
Biopharmaceutical company Immuneering Corporation recently announced the United States Food and Drug Administration’s (FDA) clearance of their Investigational New Drug (IND) application. This landmark approval gives Immuneering the opportunity to move forward with their groundbreaking Phase 1/2a clinical trial of IMM-6-415 in patients suffering from advanced solid tumor cancers. Notably, this includes cancers that exhibit RAS or RAF mutations. Based in Cambridge, Mass., Immuneering is well known for employing bioinformatic approaches to create and develop novel pipeline therapeutics that can make significant impact in tackling disorders with high unmet needs. With the clearance by the FDA, Immune...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
Sources:
Immuneering Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Immuneering Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
